Pacira BioSciences, Inc.
http://www.pacira.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacira BioSciences, Inc.
Heron Overcomes Two CRLs To Win Zynrelef Approval In Post-Op Pain
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
Keeping Track: Zegalogue Joins Hypoglycemia Space; Keytruda Earns First-Line Esophageal Cancer Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
First EMA Nod For Generic Xarelto; Apotex Pulls Upkanz For Neurodegenerative Disease
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Medical Devices
- Surgical Equipment & Devices
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- Blue Acquisition Corp.
- DepoTech Corp.
- myoscience, Inc.
- Pacira CryoTech, Inc.
- Pacira Pharmaceuticals, Inc.
- SkyePharma Inc.